Loop Capital Begins Coverage on Humana (NYSE:HUM)

Equities researchers at Loop Capital began coverage on shares of Humana (NYSE:HUMGet Rating) in a report released on Thursday, The Fly reports. The brokerage set a “buy” rating on the insurance provider’s stock.

Several other research firms have also recently weighed in on HUM. UBS Group upgraded Humana from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $486.00 to $520.00 in a report on Wednesday, April 13th. Sanford C. Bernstein initiated coverage on Humana in a research note on Thursday, May 26th. They set a “market perform” rating and a $506.00 price objective for the company. Morgan Stanley lifted their target price on Humana from $410.00 to $436.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 9th. StockNews.com raised Humana from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 20th. Finally, Wells Fargo & Company lifted their price objective on Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a report on Wednesday, May 25th. Seven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $492.51.

Shares of NYSE HUM traded down $9.89 during trading on Thursday, reaching $423.33. 38,928 shares of the stock traded hands, compared to its average volume of 1,123,293. Humana has a 52-week low of $351.20 and a 52-week high of $472.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. The company has a 50-day moving average of $444.28 and a 200-day moving average of $433.40. The stock has a market capitalization of $53.55 billion, a P/E ratio of 17.96, a price-to-earnings-growth ratio of 1.28 and a beta of 0.86.

Humana (NYSE:HUMGet Rating) last announced its earnings results on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share for the quarter, topping analysts’ consensus estimates of $6.83 by $1.21. The business had revenue of $23.97 billion for the quarter, compared to analyst estimates of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company earned $7.67 EPS. Analysts expect that Humana will post 24.65 earnings per share for the current fiscal year.

In related news, CAO William Kevin Fleming sold 3,210 shares of Humana stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $449.68, for a total transaction of $1,443,472.80. Following the transaction, the chief accounting officer now directly owns 884 shares in the company, valued at $397,517.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samir Deshpande sold 3,957 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $434.19, for a total value of $1,718,089.83. Following the completion of the transaction, the insider now owns 5,529 shares in the company, valued at $2,400,636.51. The disclosure for this sale can be found here. Insiders have sold 10,644 shares of company stock worth $4,702,360 over the last quarter. 0.39% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in HUM. Moors & Cabot Inc. lifted its position in shares of Humana by 1.7% in the third quarter. Moors & Cabot Inc. now owns 1,455 shares of the insurance provider’s stock worth $567,000 after buying an additional 24 shares in the last quarter. Glassman Wealth Services lifted its position in shares of Humana by 10.5% in the fourth quarter. Glassman Wealth Services now owns 252 shares of the insurance provider’s stock worth $117,000 after buying an additional 24 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Humana by 3.0% in the first quarter. Quadrant Capital Group LLC now owns 845 shares of the insurance provider’s stock worth $368,000 after buying an additional 25 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its position in shares of Humana by 3.5% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 730 shares of the insurance provider’s stock worth $318,000 after buying an additional 25 shares in the last quarter. Finally, B. Riley Wealth Management Inc. lifted its position in shares of Humana by 5.0% in the fourth quarter. B. Riley Wealth Management Inc. now owns 546 shares of the insurance provider’s stock worth $253,000 after buying an additional 26 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Humana (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

The Fly logo

Analyst Recommendations for Humana (NYSE:HUM)

Want More Great Investing Ideas?

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.